Investor Relations

Get stock updates, FAQs, and more.

go to Investor Relations

Our Best-in-Class Companies

Find a powerful partner that promises results.

find an inVentiv Health company

Contact Information

If you are representing a media outlet and have immediate questions, please contact:

MARCIA FREDERICK
614.543.6281
mfrederick@inventivhealth.com

Press Releases

Chamberlain Healthcare Public Relations Appoints Mark Cater Managing Director of London Office

Company strengthens commitment to London-New York global teams

LONDON AND NEW YORK, January 4, 2010 — Chamberlain Healthcare Public Relations, an inVentiv Health (NASDAQ: VTIV) company, today announced the appointment of Mark John Cater to the position of Managing Director of its London office.  Operating in London since 2008, Chamberlain has built a small but significant presence working on behalf of several of its U.S.-based worldwide pharmaceutical clients on their global brands and issues.
 
“Given our brief tenure but serious intentions in London, it is important we attract the best leadership,” said Richard Chamberlain, President, Chamberlain Healthcare Public Relations. “Mark’s twenty-two years of public relations experience in both the public and private sectors across the U.K., European & U.S. markets makes him exceptionally qualified to lead our London team, support our worldwide clients and further our global communications efforts,” said Chamberlain.
Prior to joining Chamberlain, Cater was Regional Director, Europe, Middle East, Africa & India for Cohn & Wolfe, and chief executive officer of GCI U.K. prior to the company merging in 2008 with Cohn & Wolfe.  Mark previously spent six years in various leadership roles as partner and director at public relations agency Ketchum where he was responsible for the company’s worldwide healthcare practice and served in both the London and New York offices.
 
“I am particularly excited about the opportunities ahead with Chamberlain,” said Mark Cater.  “Healthcare companies are again experimenting aggressively with communications and they want partners who complement and challenge them in the critical markets.  London and New York clients, regardless of where they are headquartered, are especially keen on sound judgment, innovation and results.  I see those qualities as Chamberlain’s strong suits whether programming in Europe, North America, or globally,” said Cater.
Chamberlain has organized its global teams in London and New York around the core beliefs that science is the backbone of a brand’s promise, and that a global communications environment requires uniform service values, professional ethics and cohesive and consultative leadership.
In his new role, Cater will also become a member of the agency management team working with Chamberlain’s senior leaders including Jonathan Wilson, Managing Director and Global Practice Head, with whom he previously worked in both London and New York, as well as Deborah Cohen, Managing Partner, and Executive Vice Presidents Jennifer O’Neill and Reba Auslander.

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing; and our inability to determine the actual time at which the liquidation of the Columbia Strategic Cash Portfolio will be completed or the total losses that we will actually realize from that investment vehicle. . Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.